Eddie Gray, OBE

Eddie has over forty years of global experience in the life sciences industry, twenty-five years of that time at GlaxoSmithKline PLC culminating as President of the European Pharmaceutical business and member of the Corporate Executive Team. During this time, he was extensively involved in leadership of vaccine and other anti-infectives businesses. From 2013-2019 he was CEO of Dynavax Technologies, a California biotechnology company. During his tenure, Dynavax raised sufficient funds to plan and complete the clinical program, achieve FDA approval and successfully launch its first product, a vaccine for prevention of Hepatitis B. Gray was later appointed Chair of the UK Government Covid-19 Antivirals Taskforce during the peak of the pandemic, successfully identifying and securing supply of at-home treatments for the most vulnerable patients who contracted the virus. He was appointed OBE in recognition of this contribution. He is a Board member of The Independent Press Standards Organisation (IPSO), the UK press regulatory body. Gray received his bachelor’s degree from the University of London and his MBA from Cranfield School of Management.